Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ATXI
CUSIPN/A
Phone781-652-4500
Debt
Debt-to-Equity RatioN/A
Current Ratio2.14
Quick Ratio2.14
Price-To-Earnings
Trailing P/E Ratio-1.95
Forward P/E Ratio-1.41
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.89 per share
Price / Book1.72
Profitability
EPS (Most Recent Fiscal Year)($1.77)
Net Income$-12,250,000.00
Net MarginsN/A
Return on Equity-167.30%
Return on Assets-132.67%
Miscellaneous
Employees2
Outstanding Shares10,550,000
Market Cap$36.10 million
Avenue Therapeutics (NASDAQ:ATXI) Frequently Asked Questions
What is Avenue Therapeutics' stock symbol?
Avenue Therapeutics trades on the NASDAQ under the ticker symbol "ATXI."
How were Avenue Therapeutics' earnings last quarter?
Avenue Therapeutics Inc (NASDAQ:ATXI) announced its quarterly earnings data on Tuesday, August, 14th. The company reported ($0.45) EPS for the quarter, beating the Zacks' consensus estimate of ($0.68) by $0.23. View Avenue Therapeutics' Earnings History.
When is Avenue Therapeutics' next earnings date?
What price target have analysts set for ATXI?
2 analysts have issued 1-year price targets for Avenue Therapeutics' stock. Their predictions range from $8.00 to $11.00. On average, they anticipate Avenue Therapeutics' stock price to reach $9.50 in the next year. This suggests a possible upside of 191.4% from the stock's current price. View Analyst Price Targets for Avenue Therapeutics.
What is the consensus analysts' recommendation for Avenue Therapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avenue Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avenue Therapeutics.
Who are some of Avenue Therapeutics' key competitors?
Some companies that are related to Avenue Therapeutics include CytoDyn (CYDY), Intec Pharma (NTEC), Correvio Pharma (CORV), Sierra Oncology (SRRA), Ovid Therapeutics (OVID), Infinity Pharmaceuticals (INFI), Chembio Diagnostics (CEMI), XOMA (XOMA), Sol Gel Technologies (SLGL), TapImmune (TPIV), Trevena (TRVN), Juniper Pharmaceuticals (JNP), ContraFect (CFRX), Steadymed (STDY) and MOTIF BIO PLC/S (MTFB).
Who are Avenue Therapeutics' key executives?
Avenue Therapeutics' management team includes the folowing people:
- Dr. Lindsay Allan Rosenwald, Exec. Chairman (Age 63)
- Dr. Lucy Lu, Pres, CEO & Director (Age 43)
- Mr. Joseph Walter Vazzano, VP of Fin. & Accounting, Principal Financial Officer and controller (Age 34)
- Dr. Scott A. Reines, Interim Chief Medical Officer (Age 71)
When did Avenue Therapeutics IPO?
(ATXI) raised $30 million in an initial public offering on Tuesday, June 27th 2017. The company issued 5,000,000 shares at a price of $5.00-$7.00 per share. Oppenheimer served as the underwriter for the IPO and National Securities Corp. was co-manager.
How do I buy shares of Avenue Therapeutics?
Shares of ATXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Avenue Therapeutics' stock price today?
One share of ATXI stock can currently be purchased for approximately $3.26.
How big of a company is Avenue Therapeutics?
Avenue Therapeutics has a market capitalization of $36.10 million. The company earns $-12,250,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis. Avenue Therapeutics employs 2 workers across the globe.
What is Avenue Therapeutics' official website?
How can I contact Avenue Therapeutics?
Avenue Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]
MarketBeat Community Rating for Avenue Therapeutics (NASDAQ ATXI)
MarketBeat's community ratings are surveys of what our community members think about Avenue Therapeutics and other stocks. Vote "Outperform" if you believe ATXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
